Clinical Trial Update: Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update for ibudilast (MN-166) in amyotrophic lateral sclerosis, outlining a 12-month treatment period followed by a 6-month open-label extension …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• ibudilast (ibudilast)

Snippet

Sponsor: MediciNova | Conditions: Amyotrophic Lateral Sclerosis | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING